Fig. 2: Overview of the study cohort and patient characteristics. | Nature Communications

Fig. 2: Overview of the study cohort and patient characteristics.

From: Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer

Fig. 2

This study cohort comprised patients who received comprehensive genomic profiling (CGP) as part of routine clinical care (top). A total of 29,704 patients with tissue biopsy (TBx)-based CGP, 3339 patients with liquid biopsy (LBx)-based CGP and 712 patients with longitudinal TBx and LBx CGP were examined. Patient and specimen-level characteristics have been provided for each of these cohorts. Additional breakdown of histological subtype, site of biopsy and receptor subtype information is provided for the 712 patients with longitudinal TBx and LBx CGP. Treatment information was retrospectively reviewed in an independent de-identified clinico-genomic database (CGDB), comprising 6,757 patients with TBx CGP and 1150 patients with LBx CGP (bottom). Patient and specimen-level characteristics have been provided for each of these cohorts. Additional information such as ECOG status, lines of therapy are available for samples in the CGDB cohort. (ILC invasive lobular carcinoma, IDC invasive ductal carcinoma, TNBC triple-negative breast cancer, NOS not otherwise specified, IQR interquartile range).

Back to article page